Curie Oncology, one of Southeast Asia's fastest-growing private oncology networks, has partnered with Singapore-based health-tech company Oncoshot to deploy artificial intelligence (AI)-powered clinical research tools that help patients gain faster access to clinical trials.
The partnership marks one of the first real-world implementations of oncology-focused AI within a regional private cancer group, complementing earlier deployments across Singapore's public healthcare system.
Curie Oncology currently runs numerous clinical trials across Singapore and Malaysia. As the group expands its research footprint, the volume of data required to identify eligible patients has increased significantly.
Digitalisation in healthcare has generated large volumes of data with valuable clinical insights. This information ranges from structured datasets like lab results to unstructured content such as free-text notes created inside and outside clinical environments. Yet over 80% of health data is unstructured, making it difficult for research teams to process efficiently or consistently. These limitations create significant barriers for researchers who need reliable, analysis-ready information.
Through the partnership, Curie Oncology is now using Oncoshot's AI tools to rapidly structure and analyse clinical data, enabling its oncologists and research teams to identify eligible patients sooner and offer access to ongoing trials more efficiently.
Curie Oncology is among the first private oncology networks in Asia to deploy Oncoshot's AI platform, extending the company's work with earlier public-facing collaborations across Singapore's cancer research ecosystem.
